The approval is the 14 th for Keytruda, extending its use into a tenth ... for Opdivo in second-line HCC after it became clear the EMA would not accept the data that backed its US approval.
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...
Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028.
Hosted on MSN2mon
China NMPA approves MSD’s KEYTRUDA for stages of NSCLCChina National Medical Products Administration (NMPA) has approved MSD’s KEYTRUDA for use in conjunction with platinum-containing chemotherapy as a neoadjuvant treatment and as a single agent ...
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
(RTTNews) - Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback